It just depends on the season of life and wellness goals at the time
d , Cell death- i nducing DFFA-like effector a (Cidea1)
Retatrutide led to dose-dependent reductions in body weight of up to 24.2% at 48 weeks, with a safety profile comparable to other GLP-1-based therapies. Jastreboff et al., NEJM Secondary Benefits Improved HbA1c in both diabetic and pre-diabetic participants Significant reductions in liver fat (a marker for NAFLD/NASH reversal) Lowered triglycerides, LDL, and inflammatory markers Favorable impact on blood pressure and fasting insulin levels Tolerability and Safety Most side effects were GI-related and dose-dependent : Nausea Constipation Occasional vomiting All were similar in frequency and severity to those seen in Semaglutide trials No serious adverse events were reported Dropout rates were low across all dose groups These results suggest Retatrutide may offer not only more dramatic weight loss , but also better metabolic improvements and potential muscle-sparing advantages making it a standout candidate for both medical and performance-focused applications
The standard clinical recommendation is to hold for at least 90 to 120 seconds
Drawbacks: Higher doses from LillyDirect are $449 per month (and this is for vials and needles, not easy-to-use pens)
Chemist+Druggist is a trading division of Citeline, a Norstella company and operates as part of C&D Intelligence U.K
